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Introduction and objectives: Recent research has suggested that genetic factors may play an
important role in the development of drug resistance in epilepsy. It is not clear which gene
loci are responsible for the drug-resistant phenotype. Studying certain nuclear receptors
may be helpful in predicting drug response, as they regulate drug transporting proteins and
enzymes involved in their metabolism. This study focuses on one of these receptors, the
human pregnane X receptor (hPXR).
The objective was to examine the link between selected single nucleotide polymor-
phisms (SNPs) 69789A/G rs 7643645 and 66034T/C rs 13059232 hPXR and the lack of response
to epilepsy treatment.
Materials and methods: 73 patients diagnosed with drug-resistant epilepsy were included in
the study. The diagnoses were made according to the criteria published by The International
League Against Epilepsy (ILAE) in 2010. The control group was comprised of a group of 122
healthy volunteers. Genetic material isolated from the peripheral blood of the participants
was analyzed with TagMan Genotyping Assays in search of the selected hPXR polymor-
phisms.
Results: The distribution of genotypes of the 66034T/C rs 13059232 hPXR polymorphism was
signiﬁcantly different in the group with drug-resistant epilepsy and the control group.
In the drug-resistant group the CC genotype was signiﬁcantly more common compared to
the control group (50.7% vs 35.2%) p = 0.0339.
The distribution of 69789 A/G rs 7643645 hPXR genotypes was comparable in both groups.
Conclusions: There is potential association between hPXR and drug resistance but its rele-
vance for the development of drug-resistant phenotype remains to be studied.
# 2016 Published by Elsevier Sp. z o.o. on behalf of Polish Neurological Society.
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Approximately one third of epileptic patients suffer from
seizures, despite correct antiepileptic treatment. This is what
is understood by ‘‘drug-resistant’’, ‘‘intractable’’ or ‘‘refracto-
ry’’ epilepsy. Several risk factors for this form of the disease
had been identiﬁed thus far, such as the onset of symptoms in
the ﬁrst year of life, high frequency of seizures before starting
treatment, the presence of several types of seizures in one
patient, a family history of epilepsy, structural changes of the
brain, malformations of cortical development, hippocampal
sclerosis, brain tumors, tuberous sclerosis and postinﬂamma-
tory injuries, among others [1].
Nevertheless it is often difﬁcult to pinpoint the cause of
drastically different responses to treatment with antiepileptic
drugs (AED) in patients with the same diagnosis and type of
epileptic seizures [2,3]. Genetic factors modifying the pharma-
cokinetic and pharmacodynamic properties of said drugs may
be a cause of the phenomenon.
Examples of such factors include genetic polymorphisms of
certain microsomal enzymes (CYP2C9, CYP2C19) [4–6], P-
glycoprotein (also known as the multidrug resistance-associ-
ated protein) [7–11], the dysfunction of GABAA receptors [12–
14] and potassium channels [15] modifying their pharmaco-
dynamic properties.
The genetic polymorphism of the Pregnane X Receptor gene
(hPXR) is a potential risk factor for resistance to antiepileptic
drugs.
The ﬁrst reports of the hPXR receptor appeared in 1998
when the pregnanes were identiﬁed [16]. Pregnanes are the
natural ligands of the PXR receptor, after which the receptor
was named.
PXR is a nuclear receptor involved in the induction of
cytochrome P450 enzymes (CYP 2B6, CYP2B9, CYP2C8, CYP2C9,
CYP3A4) and protein transporters such as P-glycoprotein
[17–20].
These two mechanisms were considered to be plausible
sources of the drug resistance phenomenon in epilepsy, and
have since then been subject to much research.
It was later discovered that hPXR regulates the transcription
of over 150 genes, of which many are determinant of drugs'
pharmacokinetics and their effects on the body.
CYP3A, MDR1, OATP2 [21], MRP1, MRP2, MRP3 [22–24] and
UGT1A1 [25] genes are among the best documented ones.
It seems reasonable to assume that the genetic variations
within hPXR may indirectly inﬂuence many other genes that
collectively determine the individual's ability to metabolize
certain drugs and their response to treatment.
The promoter and intron 1 of the hPXR gene seem to be
particularly involved in inﬂuencing the activity of the P450
CYP3A4 – the isozyme responsible for metabolizing antiepi-
leptic drugs, among others. Out of 89 known single nucleo-
tide polymorphisms (SNP) of the promoter and intron 1,
several modify the activity of CYP3A4: SNP 44477T>C, SNP
63396C>T, SNP 56348C>A, SNP 69789A>G and SNP 66034T>C
[26].
Based on that data, we designed this study to try to assess
the link between two SNPs, 69789A/G rs7643645 and 66034T/C
rs13059232 hPXR, and drug-resistant epilepsy.2. Material and methods
2.1. Patients
73 patients (36 women and 37 men, with an average age of 41.9
 16.1 years old) with epilepsy not responding to treatment
took part in the study. All patients were followed by the
Department of Neurology and Stroke at the Central Veterans'
Hospital in Lodz between 2013 and 2014. The formal criterion
for the inclusion was a diagnosis of drug-resistant epilepsy
according to the 2010 consensus deﬁnition by the Internation-
al League Against Epilepsy (ILAE). This deﬁnition describes the
failure of adequate trials of two tolerated, appropriately
chosen and used antiepileptic drug schedules (whether as
monotherapies or in combination) to achieve sustained
seizure freedom. Patients who presented other risk factors
predisposing them to negative outcomes, i.e. disease onset
before 1 year of age, family history of epilepsy and structural
changes of the brain, were not included in the study. All
patients had undergone an imaging study of the brain, an EEG
and a thorough neurological examination. The control group
was comprised of 122 healthy volunteers (65 women and 57
men), between ages 25 and 65, with an average age of 37.3
 11.2 years old. Genetic material was isolated from peripheral
blood samples. All participants signed a written notice of
informed consent after ﬁrst receiving all relevant information.
The study was approved by the Bioethical Committee attached
to the Medical University of Lodz, approval no. RNN/263/13/KB.
2.2. Genotyping analysis
Genomic DNA was isolated from 200 mL of blood using the
Blood DNA Puriﬁcation Kit (EURex) according to the manu-
facturer's protocol. DNA was quantiﬁed using a PicoDrop
spectrophotometer (Picodrop Limited) and either immediately
used for PCR reaction or stored at 20 8C. The hPXR gene single-
nucleotide polymorphisms were analyzed using commercially
available pre-made Taq Man SNP Genotyping Assays (Thermo
Fisher): polymorphism C/T (rs13059232) – assay ID:
C__30747427_20 and polymorphism A/G (rs7643645) – assay
ID: C___1834250_10.
The PCR was performed using the GeneAmp PCR System
9700 (Applied Biosystems) in 25 mL reaction volume containing
10 ng DNA, 12.5 mL TaqMan® Universal PCR Master Mix and
1.25 mL (40) of the appropriate TagMan® SNP Genotyping
Assay. The PCR thermal cycling was as follows: initial
denaturation at 95 8C for 10 min; 40 cycles of 15 s at 92 8C
and 1 min at 60 8C. Each 96-well plate contained tested
samples and 3 reaction mixtures without DNA template (no-
template control). End-point ﬂuorescent intensities of each
probe were monitored using 7900HT Fast Real-Time PCR
System (Applied Biosystems). The genotypes were determined
automatically and veriﬁed visually using Sequence Detection
System 2.3 Software.
2.3. Statistical analysis
Both descriptive and inferential statistical methods were used
to analyze the data. Proportions, or fractions, were calculated
Table 3 – Genotypic distributions of the hPXR poly-
morphisms combination.
Combination of
polymorphisms
Studied
group
Control group p
N % N %
CT/AG 22 30.1% 39 32.0% 0.7896
CT/GG 5 6.8% 7 5.7% 0.7546
CC/AA 27 37.0% 27 22.1% 0.0249
CC/AG 10 13.7% 14 11.5% 0.6474
TT/AG 3 4.1% 4 3.3% 0.9236
CT/AA 1 1.4% 15 12.3% 0.0155
TT/AA 1 1.4% 1 0.8% 0.7149
TT/GG 3 4.1% 13 10.7% 0.1795
CC/GG 1 1.4% 2 1.6% 0.6504
Total 73 100.0% 122 100.0%
Bold indicates signiﬁcant value at p < 0.05.
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subgroups, these proportions were presented as percentages.
Because grouping the participants by their genotypes yielded
many small subgroups, these results were left as fractions.
Pearson's Chi-squared test was used to compare how often
each of the possible genotypes was found in the studied group
and the control group. The Chi-squared test was also used to
search for additional possible links between speciﬁc geno-
types, frequency of seizures and the number of used drugs.
Reference charts were used to determine whether the
results of various comparisons were statistically signiﬁcant.
The distribution of genotypes in both studied and control
groups was checked against the Hardy-Weinberg principle.
Calculations were carried out using the Chi-squared test.
The cutoff point for the Hardy-Weinberg principle was
p < 0.05.
3. Results
The distribution of genotypes of both studied polymorphisms
in the studied and the control group complied with the Hardy-
Weinberg equilibrium ( p > 0.05).
An analysis using the Pearson's Chi-squared test revealed a
signiﬁcant difference in the distribution of the various
genotypes of the 66034T/C rs 13059232 hPXR SNP in the
studied and the control group. The CC genotype was
statistically more common ( p = 0.0339) in the studied group
(50.7%) than in the control group (35.2%). The results for the
remaining two genotypes were not statistically signiﬁcant
(Table 1).
The distribution of genotypes of the other studied SNP, the
69789 A/G rs 7643645 hPXR, did not reveal signiﬁcant
differences between the two groups. These results are
presented in Table 2.
The analysis of the coincidence of both hPXR polymor-
phisms (Table 3) revealed that certain combinations ofTable 1 – Genotypic distributions of the hPXR 66034T/C
polymorphism in relation to AED response.
Genotype Studied group Control group p
N % N %
CT 29 39.7% 61 50.0% 0.1637
CC 37 50.7% 43 35.2% 0.0339
TT 7 9.6% 18 14.8% 0.2964
Total 73 100.0% 122 100.0%
Bold indicates signiﬁcant value at p < 0.05.
Table 2 – Genotypic distributions of the hPXR 69789 A/G
polymorphism in relation to AED response.
Genotype Studied group Control group p
N % N %
AG 35 47.9% 57 46.7% 0.8684
AA 30 41.1% 43 35.2% 0.4140
GG 8 11.0% 22 18.0% 0.1852
Total 73 100.0% 122 100.0%polymorphisms occur signiﬁcantly more commonly in either
the studied or the controlled group.
The Chi-squared test conﬁrmed ( p = 0.0249) that the CC/AA
combination was signiﬁcantly more common in the studied
group (37.0% vs 22.1% in the control group).
In the control group it was the CT/AA genotype association
that proved to be non-random ( p = 0.0155), with 1.4% preva-
lence in the studied group but 12.3% in the control group.
The correlation between patient genotype and the frequen-
cy of epileptic seizures was statistically signiﬁcant ( p < 0.001).
The CC/AA genotype was the most strongly correlated with the
frequency of seizures. Half of the patients with this genotype
suffered from frequent seizures (0.50 fraction). They were also
common in the CC/AG genotype (0.20 fraction) and the CT/GG
genotype (0.33 fraction). None of the patients with the TT/GG
genotype suffered from frequent or very frequent seizures
(Table 4).
All patients in the studied group were treated with 2 or 3
antiepileptic drugs. No statistically signiﬁcant correlation was
found between the number of drugs used and patients'
genotypes ( p > 0.05) (Table 5).
4. Discussion
The hPXR receptor regulates the drug metabolism by means of
expression of certain enzymes, drug transport through cell
membranes, and their excretion. The genetic variety within
the hPXR gene is therefore a likely cause of differences in
individuals' responses to antiepileptic drugs and consequently
the efﬁcacy thereof.
Few mentions of the signiﬁcance of the hPXR variance in
epilepsy have been published so far.
A Malaysian study tried to establish whether the G7635A
hPXR polymorphism changed outcomes in monotherapy with
either of the two most commonly used antiepileptic drugs:
valproic acid and carbamazepine. No signiﬁcant differences
were found for the group of 685 Malaysian patients [27].
An analogous study focusing on 11193T>C and 11156A>C
hPXR polymorphisms found no signiﬁcant differences in
responses to antiepileptic drugs in the Chinese population [28].
A Japanese study from march 2014 looked for correlation
between the polymorphisms of (PXR)*1B gene, hepatocyte
Table 4 – Relationship between genotype and frequency of seizures.
Seizure frequency CC/AA CT/AG CC/AG CT/GG TT/GG
N Fraction N Fraction N Fraction N Fraction N Fraction
Very frequent 2 0.08 – – 1 0.10 – – – –
Frequent 11 0.42 2 0.10 1 0.10 2 0.33 – –
Rare 13 0.50 18 0.90 8 0.80 4 0.67 3 1.00
Total 26 1.00 20 1.00 10 1.00 6 1.00 3 1.00
Very frequent: >10 seizures a month; frequent: 5 > x > 10 seizures a month; Rare: <5 seizures a month.
Table 5 – Relationship between the genotype and the number of drugs used.
Number of
drugs used
CC/AA CT/AG CC/AG CT/GG TT/GG
N Fraction N Fraction N Fraction N Fraction N Fraction
2 20 0.77 11 0.55 9 0.90 6 1.00 2 0.67
3 6 0.23 9 0.45 1 0.10 – – 1 0.33
Total 26 1.00 20 1.00 10 1.00 6 1.00 3 1.00
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chrome P450 3A5*3 and the response to treatment with
carbamazepine in 168 patients. Even though neither of these
genetic factors signiﬁcantly changed the response to treat-
ment in isolation, the combination of the PXR*1B and HNF4a
rs2071197 polymorphisms had an inﬂuence on the metabo-
lism of carbamazepine [29].
We have not found studies pointing to a speciﬁc polymor-
phism of hPXR increasing the risk of drug resistance in the
current body of literature.
While it is acknowledged that epileptic patients responding
well to treatment might have formed a more effective control
group, we saw issues with this approach.
In our opinion, selection of patients with epilepsy who
demonstrate a ‘‘good response’’ to an antiepileptic drug
maintained for 10–20 years (for sake of statistical comparisons)
is a difﬁcult task, because a drug is usually gradually
discontinued after 3 years of effective treatment. The treatment
is re-instated if seizures appear again after discontinuation of
the drug.
Evolution of epilepsy into drug-resistant disease is another
possible scenario. According to our observations, majority of
patients with drug-resistant epilepsy are being treated for
many years (usually more than 10) – and often at the
beginning of the treatment their seizures were drug-respon-
sive. At that time it is not possible to predict if the drug-
resistance will develop in the future. Probably there is a group
of patients who demonstrate long-term response to an
appropriately chosen monotherapy, but the size of that group
is low, and that kind of group could not be assembled within
the limited time of material collection. Analysing results of
the study a question may be also asked if there is an
association between the 66034T/C polymorphism of the hPXR
gene and epilepsy itself. Authors have presented a causal
relationship between hPXR and a possible effect on pharma-
cokinetics of anti-epileptics. There have been no reports from
the GWAS study indicating association of that locus with
epilepsy itself. Of course we cannot exclude the possibility of
such association.
The study was designed as a screening aimed at determi-
nation if there really was a potential association (deduced on apurely theoretical basis) between hPXR and drug-resistance.
Based on the presented results it may be stated that such
association exists, although other interpretations are also
plausible. To conﬁrm it ﬁnally the study group should be
increased in size and some additional control groups should be
created, e.g. patients responding to anti-epileptic therapy or
drug-resistant schizophrenia etc.
Despite the limitations mentioned above, this study is the
ﬁrst of its kind to demonstrate a potential link between
66034T/C polymorphism of the hPXR gene and resistance to
antiepileptic treatment.
We have also observed a correlation between certain
genotypes predisposed to drug-resistant epilepsy and a higher
frequency of epileptic seizures.
We believe that the preliminary results are compelling and
warrant further research in the area, as well as a validation of
our ﬁndings in other populations.
5. Conclusion
The analysis of our results suggests a possible association
between the genotype 66034CC in terms of the 66034T/C
polymorphism of hPXR gene and the absence of a satisfactory
response to anti-epileptic treatment, although other inter-
pretations are not completely excluded. It was observed that
the 66044CC genotype may predispose to increased frequency
of epileptic seizures, and therefore be indirectly correlated
with severity of the condition. Considering the fact that the
control group was composed of healthy individuals, at the
current stage of research a potential correlation between the
66034T/C polymorphism and epilepsy as such is possible. A
correlation of that kind has not been mentioned in available
literature. Our results constitute a starting point for further
studies using larger and ethnically different populations,
including responders to treatment.
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